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↑What is “already known” in this topic: 
The quality assessment of some types of articles is comprehen-
sively implemented and published; however, the quality as-
sessment of systematic reviews with meta-analyses (SRMA) 
articles has not yet been completely performed since few arti-
cles have been published in the pharmaceutical field.   
 
→What this article adds: 
Researchers and readers interested in SRMA studies are aware 
of the weaknesses of existing articles and pay attention to the 
results of such articles to conduct their future studies.  
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Abstract 
    Background: Meta-analyses, like all other studies, may be poorly designed and implemented. This study was designed to determine 
the quality of meta-analyses in systematic reviews in the field of pharmaceutical research in Iran. 
   Methods: Web of Science Core Collection, EMBASE, Ovid Medline, CINAHL, Scopus, and PubMed were systematically searched 
on June 4, 2017. The search was limited to the researches in the field of pharmaceutical studies. Based on inclusion criteria, 104 
systematic reviews with meta-analysis (SRMA) were selected and assessed using quality assessment tools introduced by Higgins. 
   Results: Participants, experimental interventions, and outcomes were reported in all the articles. Comparator intervention and study 
design were correctly reported in 103 (99.04%) and 101 (97.12%) articles, respectively. The comprehensive search strategy was 
available only in 48 articles (46.16%), and there was no evidence of a comprehensive search in 56 articles (53.84%). Risk of bias was 
investigated in 78 articles (75%). Also, funnel plots were the most commonly used method for reporting the bias in 64 articles 
(46.42%). 
   Conclusion: In many of the meta-analyses, several items of the tool that represented a high-quality meta-analysis were absent. 
According to the findings, the comprehensive search and quality assessment were not at an appropriate level. Thus, the importance of 
reproducibility of information and quality assessment of included studies should be emphasized. 
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Introduction 
In the field of medicine, the SRMA articles (systematic 
reviews with meta-analyses) collate and analyze the re-
sults of several studies with similar objectives and results 
to provide a more valid and reliable estimate of the effect 
of the drug dose or other interventions (1). 
The effect size of the pharmacological interventions is 
directly related to human health and life in most cases; 
therefore, the meta-analyzers provide more reliable results 
through aggregation of similar studies that include larger 
sample size and a shorter confidence interval and higher 
accuracy (2).   
An appropriate and accurate evaluation of the quality of 
articles and the publication bias are inseparable parts that 
make the conclusion of this type of research valid (3). The 
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recommendations and results that meta-analyses offer help 
researchers in the treatment of diseases based on the accu-
racy and precision with which the research has been done 
and written. In addition, adverse events were reported in 
clinical trials in certain circumstances. Writing adverse 
events in review articles makes researchers aware of the 
complications of interventions; therefore, the necessity of 
increasing the accuracy and comprehensiveness in this 
type of research is evident (4), to a degree that it is essen-
tial to mention the item related to the adverse events of 
drugs in the quality assessment tools (5). Meta-analyses 
with inappropriate statistics, poor resource, results with 
selection bias, and unfavorable access to the internet for 
sales and advertising increased the importance of paying 
attention to the quality assessment methods in this area (6, 
7). Different biases have been observed in meta-analytical 
articles sponsored by a specific industry. Transparency 
and reporting the results in accordance with the aims of 
the organization are among the most prominent examples 
(7, 8).  
Therefore, it is essential to assess the quality of SRMA 
studies. Several studies, including review articles and me-
ta-analyses, have reported the use of various tools in 
quality assessment and measurement; PRISMA (9), AM-
STRA (10), and quality assessment tool by Higgins et al 
are a few examples (11). In recent years, meta-analyses 
have played a significant role in the development of 
pharmaceutical science, and the specific analyses of the 
issues of efficacy and safety have been discussed more 
than other issues. In the meantime, the need for accuracy 
is more felt. This study was conducted to assess the quali-
ty of Iranian SRMA articles in the field of pharmaceutical 
research based on a quality assessment tool proposed by 
Higgins et al (11). Hence, the importance of the results of 
SRMA articles in medicine and pharmacology is a chal-
lenge. 
 
Methods 
Search strategy 
One of the authors (F S) performed the online search for 
pharmacological meta-analysis articles in Web of Science 
Core Collection, EMBASE, Ovid Medline, CINAHL, 
Scopus, and PubMed (("Iran"[Mesh] OR Iran*[tiab] OR 
Persia*[tiab]) AND ("Meta-Analysis"[Publication Type] 
OR "Meta-Analysis as Topic"[Mesh] OR Meta-
Analy*[tiab] OR Metaanalys*[tiab])) without date or lan-
guage limitations on June 4, 2017. The studies were re-
trieved based on their title, abstract, and authors’ names in 
SRMA articles. For selective studies, the articles were 
independently screened by 2 of the authors (F S and A A) 
and the controversial issues were resolved in a debate. 
 
Study selection and eligibility criteria 
The inclusion criteria for the study were as follow: 
1) Study design: systematic review and meta-analysis. 
 
Data extraction 
Two of the authors (A A and L M) extracted the data 
from the selected articles and a third author (F S) looked 
for contradictions. Articles selected for the study were 
reviewed based on the following criteria: 1. basic infor-
mation; 2. data sources; 3. analysis of individual studies 
by the meta-analysis; 4. meta-analysis; and 5. reporting 
and interpretation. 
The tool used in this study were consistent with the 
AMSTRA and Cochrane Handbook for Systematic Re-
views of Interventions, and review articles and expert 
group were also used. The tool was used in pharmaceuti-
cal SRMA studies (11, 12). Unlike other quality assess-
ment tools, this tool emphasizes on statistical and interpre-
tative items. The main purpose of this tool is to evaluate 
the quality of meta-analyses for efficacy and safety in the 
pharmaceutical field. 
 
Results 
After screening the articles based on the inclusion crite-
ria, 104 SRMA articles in the field of pharmaceutical re-
search published since 2006 were investigated (Fig. 1). 
The growing trend of the articles over the years can be 
observed in Figure 2, and this growth was significant dur-
ing 2015 and 2016 compared to the previous years. 
Indicators related to the research question (eg, how to 
search and select information sources) are presented in 
Table 1. Regarding the inclusion criteria of the study, ex-
cept for the study designs (97.1%) and the comparator 
intervention (99.0%), other elements were completely 
expressed in relation to the question. Published literature 
and bibliographic databases were searched in all articles; 
however, other elements were less explored. Of all arti-
cles, 93.2% of data disclosed by industry were not sought, 
although 43 (41.3%) SRMA articles considered limita-
tions in terms of their characteristics, publication status, or 
language in literature search. The search strategy was pre-
sented in 26 articles (25.5%), not presented in 15 articles 
(14.5%), and was partially presented in 47 articles 
(45.1%). Search for evidence was reasonably and compre-
hensively expressed in 48 articles (46.1%), and 56 articles 
(53.8%) did not have any evidence for research compre-
hensiveness. The selection of studies was independently 
done by 2 or more people in 72 articles (69.23%), by one 
person in 3 articles (2.88%), and was unstated or unclear 
in 29 articles (27.89%). 
The quality assessment of methodology are presented in 
Table 2. The quality assessment of studies was performed 
in 78 (75%) SRMA articles, 22 (21.15%) of which were 
clear, and 4 (3.85%) were unclear in the quality assess-
ment. Scale (eg, Jadad) was used to evaluate quality of 
methodology in 55 (70.5%) SRMA articles, the Cochrane 
risk of bias assessment tool was used in 20 (25.7%) arti-
cles, and checklist was used in 3 (3.8%) articles. 
In 6 articles (5.44%), a precise method was used to fol-
low the outcome in missing data; in 12 articles (11.54%), 
no method was presented; and in 86 articles (82.7%), out-
comes were unclear and data were lost. Other types of 
studies in which the authors have been included in their 
researches are shown in Table 2. Also, comparisons were 
reasonable in 95 SRMA articles (90.38%), the groups 
were not selected correctly in 5 articles (4.81%), and 
comparisons were unclear in 5 articles (4.81%). Moreo-
ver, the sensible outcome was reasonable and accurate in 
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97 articles (93.27%), it was not logical in 2 articles 
(1.92%), and was unclear in 5 articles (4.81%). 
The double counting of individual studies was men-
tioned in 76 articles (73.08%), not mentioned in 4 articles 
(3.85%), and was unclear in 24 articles (23.08%). The 
methods used to assess heterogeneity in the included 
SRMA studies are shown in Figure 3. Homogeneity was 
investigated only in 1% of SRMA articles. Synthesis 
methods in SRMA articles are shown in Table 3. Funnel 
plot had the highest frequency in reporting the publication 
bias. Synthesis methods were classic-basic in 79 (76.7%) 
and classic-advance in 25 (23.3%) of the reviewed arti-
cles. Sensible strategy was seen in 53 articles (51%), was 
unclear in 32 articles (30.8%), and was clear in 19 articles 
 
Fig. 1. PRISMA flow diagram 
 
 
Fig. 2. Distribution of the year of publication 
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(18.2%). Subgroup analyses were good in 24 articles 
(23.1%), unclear in 19 articles (18.3%), not applicable in 
53 articles (51%), and none in 8 articles (7.7%). The ap-
propriateness of interpretation of the subgroup analyses in 
SRMA articles was correct in 47 articles (45.2%), unclear 
in 15 articles (14.4%), not applicable in 31 articles 
(29.8%), and none in 11 articles (10.9%).   
It is essential to focus on the studied variables in SRMA 
Table 1. Resource search criteria in SRMA articles 
Frequency (%) Criteria 
No (%) Yes (%) 
  Eligibility criteria were stated and suitably specific for 
0 (0) 104 (100) Participants 
0 (0) 104 (100) Experimental intervention(s) 
1 (0.99) 103 (99.04) Comparator intervention(s) 
0 (0) 104 (100) Out comes 
3 (2.88) 101 (97.12) Study designs 
  Further restriction on eligibility on studies or reports? 
Yes(n=43), No(n=45), unclear (16) 
 33 (79.74) Specify restriction 
 6 (13.95) Publication status restriction 
 3 (6.97) Language restriction  
 1 (2.32) Other restriction 
  Data for meta-analysis were sought from 
0 (0) 104 (0) Published literature 
68 (65.38) 36 (34.62) Online repositories 
97 (93.27) 7 (6.73) Correspondence with trialists 
103 (99.04) 1 (0.96) In-house IPD 
104 (100) 0 (0) Others IPD 
  The search for trials included 
0 (0) 104 (100) Bibliographic databases  
101 (97.12) 3 (2.88) Grey literature 
101 (97.12) 3 (2.88) The web  
102 (98.08) 2 (1.96) In-houses collections 
50 (48.08) 54 (51.92) Reference lists 
93 (89.42) 11 (10.58) Hand searching 
104 (100) 0 (0) Correspondence with industry 
103 (99.04) 1 (0.96) Other correspondence 
84 (80.77) 20 (19.23) Other sources 
  Which bibliographic databases are mentioned 
1 (0.96) 103 (99.04) PubMed/MEDLINE 
66 (63.46) 38 (36.54) EMBASE 
38 (36.54) 66 (63.46) CENTRAL/Cochrane Library 
50 (48.08) 54 (51.92) Science Citation Database 
14 (14) 86 (86) other(how many) 
 
Table 2. Other clinical trial designs used in the SRMA articles 
Unclear Explicitly 
excluded 
Included 
inappropriately
Included 
appropriately
Not found or not 
mention 
Study designs 
2(1.92)2(1.92) 2(1.92)19(18.27)79(75.96) Cross-over trials 
3(2.88)2(1.92) 0(0)4(3.85)95(91.35) Cluster randomized trials 
7(6.73)10(9.62) 6(5.77)14(13.46)67(64.52) Other study designs 
 
Table 3. The methods used in risk of bias and reporting 
Frequency (%) Criteria 
No (%) Yes (%) 
  Risk of bias (quality assessment) or eligibility criteria include 
46 (44.23) 58 (55.77) Generation of allocation sequence 
46 (44.23) 58 (55.77) Concealment of allocation sequence 
28 (26.92) 76 (73.08) Blinding 
31 (29.81) 73 (70.19) Attrition/drop out/ITT 
93 (89.42) 11 (10.58) Other 
  The synthesis methods used in the paper included 
3 (2.88) 101 (97.12) Pooling (no stratification by study) 
47 (45.19) 57 (54.81) Fixed-effect meta-analysis 
22 (21.15) 82 (78.85) Random-effect meta-analysis 
100 (96.15) 4 (3.85) Fixed-effect meta regression 
83 (79.81) 21 (20.19) Random-effect meta regression 
  Tools was used for assessed reporting bias 
37 (35.58) 64 (64.42) Funnel plots  
65 (62.50) 39 (37.50) Egger test 
55 (52.88) 49 (74.12) Begg-mazumdar rank correlation test 
103 (99.04) 1 (0.96) Other Funnel plots asymmetry test 
101 (97.12) 3 (2.88) Trim and Fill 
100 (96.15) 4 (3.85) Other  
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articles to judge the analysis. For example, when a studied 
variable is continuous, determining the cut-point of the 
studies is necessary. Certain important indicators consid-
ering the type of studied variables are listed in Table 4, 
and the status of each of these indicators was expressed in 
the studied SRMA articles. 
Concerning the expression of risk of bias in SRMA arti-
cles, it was fully described in 41 articles (39.42%) in the 
table, fully described in the text of 28 articles (26.92%), 
but not mentioned or unclear in 35 (33.65%) of the re-
maining articles. Table 5 presents a general description of 
the interpretation and expression of the risk of bias in the 
text of the articles. In addition, the general interpretation 
of the questions in various sections of the checklist is ex-
pressed in Table 5. Only in 12 (11.5%) of the articles, the 
funding source and the study budget were specified in the 
text; they were not mentioned in 61 articles (58.7%), and 
they were unclear in 31 articles (29.8%). 
 
Discussion 
The present study provided an overview of the trend in 
the publication of Iranian SRMA articles indexed in the 
Medline, EMBASE, CINAHL, and Web of Science Core 
Collection over the course of 11 years, and aimed to iden-
tify and improve the quality of reporting such studies. 
These types of studies use statistical methods to summa-
rize the articles to provide the readers with a glimpse of 
overwhelming majority of the published articles with dif-
ferent results. Papers published on the quality assessment 
of the methodology of articles were studied in several 
ways to either review or evaluate the quality of methodol-
ogy of meta-analyses in the articles published in journals 
and specific databases in a particular subject area or to 
compare them using different tools (13-15). The results of 
 
Fig. 3. Methods used to assess heterogeneity 
 
Table 4. Testing and reporting issues based on data type 
Not applicable No Unclear Yes Criteria 
    Issues for continuous data 
8 (7.69) 5 (4.81) 10 (9.62) 81 (77.88) Was the choice of effect size? 
44 (42.31) 3 (2.88) 46 (44.23) 11(10.58) Was skew of data a potential problem not appropriately addressed? 
    Issues for binary data 
57 (55.34) 6 (5.83) 36 (34.95) 4 (3.88) Were methods appropriate to rare events/sparse data? 
54 (51.92) 2 (1.92) 29 (27.88) 19 (18.27) Were cut-points to dichotomize continuous/ordinal out com justified? 
    Issues for time-to-event data 
100 (96.15) 0 (0) 3 (2.88) 1 (0.96) Were time-to-event data appropriately dealt with? 
    Issues for ordinal data  
93 (89.42) 0 (0) 3 (2.88) 3 (7.69) Were ordinal data appropriately dealt with? 
    Indirect comparisons 
79 (75.96) 10 (9.62) 9 (8.65) 6 (5.77) Were indirect comparisons performed appropriately? 
 
Table 5. Summary judgment in parts of tool 
Not applicable No Probably 
no 
Unclear Probably yes Yes Summary judgment 
0 
(0) 
13 
(12.50) 
11 
(10.58) 
4 
(3.58) 
14 
(13.46) 
62 
(59.62) 
Were the review methods adequate such that biases in 
location and assessment of studies were minimized or 
able to be identified? 
0 
(0) 
11 
(10.58) 
15 
(14.42) 
19 
(18.27) 
27 
(25.96) 
32 
(30.77) 
Were the individual studies analyzed appropriately 
and without avoidable bias? 
3 
(2.88) 
1 
(0.96) 
17 
(16.35) 
7 
(6.73) 
68 
(65.38) 
8 
(7.69) 
Were the basic meta-analysis method appropriate? 
0 
(0) 
2 
(1.92) 
17 
(16.35) 
9 
(8.65) 
67 
(64.42) 
9 
(8.65) 
Are the conclusions justified and the interpretation 
sound? 
D
ow
nl
oa
de
d 
fro
m
 m
jiri
.iu
ms
.ac
.ir 
at 
17
:34
 IR
DT
 on
 S
un
da
y A
pri
l 1
2th
 20
20
    
    
  [ 
DO
I: 1
0.3
41
71
/m
jiri
.34
.30
 ]  
    
 Assessing the quality of meta-analyses in systematic reviews 
 
 
 http://mjiri.iums.ac.ir 
Med J Islam Repub Iran. 2020 (6 Apr); 34:30. 
 
6 
this study examined the methodology, design, and report-
ing of pharmaceutical meta-analyses with specially de-
signed tools (11). 
The results of this study revealed that online literature 
and online repositories were often used for the meta-
analysis data searching, and search in bibliographic data-
bases and reference lists was frequently done for the clini-
cal trials. This information was presumably collected for 
the availability and familiarity of the researchers and the 
ease of searching. Insufficient familiarity with databases 
and searchable grey literature, inefficiency in providing 
the clinical trial results by the institutions, the publication 
of articles in non-English journals, nonpublication of arti-
cles with nonsignificant results and nonindexing of these 
types of journals at databases form the potential reasons 
for the use of full search strategy (16). The SRMA re-
search does not include all available articles. However, the 
validity of these resources is subject to bias, as there is no 
peer-review and as the way grey literature is done by the 
researchers is an issue that influences the results of the 
study. All of these may lead to the selection of articles 
with significant results. 
Among the bibliographic databases, PubMed/Medline, 
CENTAL Cochrane, and Web of Sciences were more 
common. Dahabreh et al (2013) reported that the use of 
the Cochrane and EMBASE databases increased over 
time, but this growth was not tangible in Medline. Based 
on the results of our study, Medline was searched as a 
resource in all the articles. The use of unpublished litera-
ture, conferences, and manual searches remained un-
changed (13). 
Adie et al (2015) made a comprehensive search in at 
least 2 databases for only 30% of the articles (17), while 
the search strategy was fully expressed in 25% of the arti-
cles, and partially in 45.19% of the articles. Among all 
examined articles, only 7% had linguistic limitations. Ho 
et al (2015), who studied the Cochrane meta-analysis on 
COPD disease, used only 10% of articles in non-English 
databases (18). 
The risk of bias or quality of assessment was observed 
in 75% of the included articles in the SRMA, of which 
70.5% used the Jadad quality tool. Zhu et al (2016) re-
ported the quality of the articles’ methodology to be 
82.3%, in which the risk of bias was assessed based on 
Cochrane checklist (39.2%) and Jadad scale (20.3%) (15). 
Adie et al (2015) assessed the risk of bias or the quality of 
the methodology in one-third of the surgical meta-
analyses (17). 
Double counting of the individual studies was clearly 
expressed in 73.08% of the articles. While evaluating the 
quality of meta-analysis in the field of depression, 5% of 
the articles were reviewed for double counting of the data 
(13). In this study, the amount of double counting was 
77.2%, and the method of data deduplication check was 
unclear in 22.8% of them (18). The qualities of reporting 
articles, bias, and quality assessment have improved over 
time. Accordingly, the checklists or tools have also been 
updated. Yao et al (2016) highlighted the quality of meta-
analyses. They mentioned that eliminating language limi-
tation in literature search and evaluating the risk of bias 
would improve the quality of meta-analyses, although 
articles indexed in the Chinese databases were weaker 
than the ones indexed in the Cochrane database (19). Ap-
propriate meta-analysis methods, avoiding language limi-
tation, publication bias, and expressing conflict of inter-
ests can improve the quality of meta-analysis. 
It is possible to determine the publication bias in the in-
cluded studies using appropriate statistical methods, which 
may lead to the overestimation of results such as language 
bias. Articles with positive results were more likely to be 
published; moreover, the majority of these articles were in 
English and they probably were retrieved more when 
searched in databases or journals. The location and inclu-
sion biases were also problematic in these studies (10, 18). 
 Considering the fact that these articles provide the 
highest level of evidence based on medicine and decision-
making, the lack of bias and accuracy of performance in 
these articles are more crucial than other articles. Eventu-
ally, the results of this study may be affected by the design 
of the studies similar to the aforementioned studies on 
topics with conflicting results and challenges. In this 
study, only 2 articles (1.9%) lacked the application of 
pooling method, for which it was revealed that meta-
analysis was not used. They had only conducted the sys-
tematic review, and meta-analysis was written mistakenly 
in the title or in the design of the study; however, accord-
ing to a study by Zhu (2016), 4.1% of the articles did not 
refer to the pooling methods (15). Higher quality of the 
articles published in journals endorsed quality reporting 
statement compared to the articles in the journals that did 
not approve those statements (14, 15). However, preregis-
tration and the published articles in Cochrane journals 
were also better than the non-Cochrane journals with re-
gards to the quality of meta-analysis and systematic re-
view (13, 17, 20). 
The use of random effect and fixed effect in the synthe-
sis methods was 78.85% and 54.81%, respectively, which 
was similar to the results of the academic financial spon-
sors of the pharmaceutical interventions compared to the 
industrial sponsors. Therefore, the synthesis methods were 
paid less attention in the studies with industrial sponsors. 
The results of this study on integrating the risk of bias, 
reporting bias, and multiplicity were slightly different 
from those of Lane et al study (13). 
The mean scores of SRMA articles that only included 
RCT were more qualitative than the studies that included 
both observational scores and RCTs (13). Impressing the 
results of the articles by institutions that provide the funds, 
especially in pharmacological research, for which a lot of 
investment and profit is required, may affect the results of 
research by publishing, not publishing, or modifying the 
data or results (15, 21).  
The attention of certain organizations to the quality of 
the report, the original articles and review articles has led 
to an increase in the precision and accuracy of the study 
design and reporting (22, 23). In this regard, the quality of 
reporting and performing meta-analyses in the field of 
medicine in the study of Philibert et al (24) was better than 
ecological areas. Increasing the quality of the methodolo-
gy in clinical trials and the validity and reliability enhance 
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the quality of the methodology in SRMA articles. When 
no comprehensive search was done in meta-analyses or 
the risk of bias and publication bias was not evaluated, the 
results were different from the clinical trials in some cir-
cumstances (13, 25). 
Although the initial focus in pharmaceutical meta-
analyses is on the efficacy of interventions, safety is also 
required in pharmaceutical strategies, which mostly de-
pends on the reliability of the data rather than on the re-
porting (25). This is required to consider the importance 
of reporting in the articles compared to the safety of inter-
ventions along with their efficacy. Eventually, the sensi-
tivity of the editors in peer-reviewed journals and their 
knowledge on the methodology of research presumably 
play a major role in the quality of articles (17, 19). Flem-
ing et al found that the articles published in clinical jour-
nals had a high impact considering their received citations. 
For each value in journal’s IF (impact factor) score, the 
quality of the methodology of articles increases by 68% 
(26). 
 
Conclusion 
After the approval and publication of CONSORT and 
PRISMA statements by journals and editorial boards, the 
quality of the already performed and reported articles was 
more scientific and identical. These elements were im-
proved in recent years and will even improve further in 
the upcoming years with further attention of scientific 
journals and communities. The quality of meta-analyses 
could improve by using appropriate methods, avoiding 
language limitation and publication bias, and expressing 
conflict of interests.  
Contribution of methodologists (epidemiologists, bio-
statisticians, and medical librarians) is essential due to 
their familiarity with the statistical methods in SRMA 
articles and information resources for comprehensive 
search. 
The articles were selected only by searching databases, 
so this was the limitation of the present study. Gray litera-
ture and hand searching were not done. In this study, it 
was assumed that SRMA articles are published in quali-
fied journals indexed in credible databases and many  da-
tabases were searched to decrease this limitation.   
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